Literature DB >> 3998772

Levodopa-induced dyskinesia: clinical observations.

A Friedman.   

Abstract

In 144 patients receiving prolonged treatment with levodopa for Parkinson's disease, an attempt was made to establish possible correlations between the incidence of levodopa-induced dyskinesias and the age of the patient at the onset of the disease, the clinical form of the disease, the duration of symptoms before initiation of the levodopa therapy, the duration of the levodopa therapy and the influence of the concomitant treatment. Levodopa-induced dyskinesia was observed in 92 patients (64%). The age at onset of the disease of patients with dyskinesia was significantly different from the age at onset of those without dyskinesia, the means being 54.8 and 68.9 years respectively. Levodopa-induced dyskinesia occurred less often in the group with preponderant tremor than in those with preponderant bradykinesia (29% vs. 69%). The patients treated with levodopa from the very beginning of their disease were less susceptible to dyskinesia than those who had parkinsonism for some time before receiving levodopa. The influence of the duration of levodopa treatment on the manifestation of dyskinesia could not be confirmed because this side-effect usually appeared during the first year of treatment. The concomitant anti-parkinsonian treatment appeared to have no influence on the incidence of dyskinesia. Biochemical and practical implications of these observations are discussed.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3998772     DOI: 10.1007/bf00314037

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  12 in total

1.  The pathogenesis of Parkinson's disease: a new hypothesis.

Authors:  A BARBEAU
Journal:  Can Med Assoc J       Date:  1962-10-13       Impact factor: 8.262

Review 2.  Theoretical implications of the use of L-dopa in parkinsonism. A review.

Authors:  H Klawans; M M Ilahi; D Shenker
Journal:  Acta Neurol Scand       Date:  1970       Impact factor: 3.209

3.  The choreoathetoid movement disorder induced by levodopa.

Authors:  C H Markham
Journal:  Clin Pharmacol Ther       Date:  1971 Mar-Apr       Impact factor: 6.875

4.  Should levodopa therapy be started early or late?

Authors:  M D Muenter
Journal:  Can J Neurol Sci       Date:  1984-02       Impact factor: 2.104

5.  [Pathomechanism of dyskinesia associated with treatment of Parkinson disease with levodopa].

Authors:  A Friedman
Journal:  Neurol Neurochir Pol       Date:  1981 Jul-Aug       Impact factor: 1.621

6.  L-dopa long-term treatment in Parkinson's disease: age-related side effects.

Authors:  M Pederzoli; F Girotti; G Scigliano; G Aiello; F Carella; T Caraceni
Journal:  Neurology       Date:  1983-11       Impact factor: 9.910

7.  Parkinsonism: onset, progression and mortality.

Authors:  M M Hoehn; M D Yahr
Journal:  Neurology       Date:  1967-05       Impact factor: 9.910

8.  [Involuntary movements as a complication of treatment of extrapyramidal disorders with L-dopa].

Authors:  A Friedman; E Markowa
Journal:  Neurol Neurochir Pol       Date:  1981 Jul-Aug       Impact factor: 1.621

9.  [Pizotifen (Sandomigran) used in the treatment of parkinsonian tremor (preliminary communication)].

Authors:  A Friedman
Journal:  Neurol Neurochir Pol       Date:  1978 May-Jun       Impact factor: 1.621

10.  The Graeme Robertson memorial lecture, 1983. The long-term prognosis of Parkinson's disease.

Authors:  G Selby
Journal:  Clin Exp Neurol       Date:  1984
View more
  2 in total

Review 1.  Levodopa-induced dyskinesia: clinical features, incidence, and risk factors.

Authors:  Tai N Tran; Trang N N Vo; Karen Frei; Daniel D Truong
Journal:  J Neural Transm (Vienna)       Date:  2018-07-03       Impact factor: 3.575

2.  Severity of Parkinson's disease is a risk factor for peak-dose dyskinesia.

Authors:  M W Horstink; J C Zijlmans; J W Pasman; H J Berger; M A van't Hof
Journal:  J Neurol Neurosurg Psychiatry       Date:  1990-03       Impact factor: 10.154

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.